CD20
Phase 1Small molecule
CD20 is one of 3 small molecule programs targeting Multiple Sclerosis (MS). It is currently in Phase 1.
1
Indications
2
Total Trials
2
Active Trials
2
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
3 competitors in Multiple Sclerosis (MS)
#DrugCompanyPhaseTrials
1Clemastine Fumarate
NovartisPreclinical
LCAR-AIO T Cells
NNanjing Legend Biotech Co.
Phase 1
CD20
TTianjin Medical University Cancer Institute and Hospital
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
TED1 trial
Sonrotoclax, Zanubrutinib and CD20mab in Untreated MCL Patients
Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT06463691·30 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CD20. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details